MD Anderson Study Explains Differing BRAF/MEK Treatment Responses in Male, Female Melanoma Patients
Source: Precision Oncology News, June 2022
NEW YORK – Androgen receptor expression contributes to BRAF/MEK inhibitor treatment resistance, particularly among male melanoma patients, according to new research out of the MD Anderson Cancer Center.
